CONX Corgenix to Host Conference Call to Discuss First Quarter Results
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company’s financial and operating performance for its quarter ended September 30, 2013, and the status of the Company’s product development and marketing activities.
Corgenix invites all those interested in hearing management’s discussion of the annual results to join the call by dialing:
U.S. attendees: (800) 862-9098
International attendees: +1 785 424 1051
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 677-6124 for U.S. participants and +1 402 220 0664 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.
Company Contact:
Corgenix Medical Corp
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations
dan@armadamedical.com
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company’s financial and operating performance for its quarter ended September 30, 2013, and the status of the Company’s product development and marketing activities.
Corgenix invites all those interested in hearing management’s discussion of the annual results to join the call by dialing:
U.S. attendees: (800) 862-9098
International attendees: +1 785 424 1051
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 677-6124 for U.S. participants and +1 402 220 0664 for international participants.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.
Company Contact:
Corgenix Medical Corp
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations
dan@armadamedical.com
